SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,337,036 | -24.5% | 157,310 | -17.7% | 0.00% | 0.0% |
| Q2 2023 | $5,746,660 | -44.1% | 191,173 | -32.6% | 0.00% | -50.0% |
| Q1 2023 | $10,281,385 | -9.6% | 283,781 | -11.0% | 0.00% | -33.3% |
| Q4 2022 | $11,373,701 | +51.5% | 318,859 | +43.8% | 0.00% | +50.0% |
| Q3 2022 | $7,506,000 | -15.6% | 221,732 | -27.9% | 0.00% | 0.0% |
| Q2 2022 | $8,893,000 | -50.0% | 307,483 | -44.1% | 0.00% | -50.0% |
| Q1 2022 | $17,779,000 | +130.7% | 550,081 | +108.1% | 0.00% | +100.0% |
| Q4 2021 | $7,708,000 | +10.5% | 264,344 | +1.0% | 0.00% | +100.0% |
| Q3 2021 | $6,977,000 | -9.8% | 261,610 | +4.1% | 0.00% | -50.0% |
| Q2 2021 | $7,739,000 | +53.1% | 251,356 | +30.2% | 0.00% | +100.0% |
| Q1 2021 | $5,056,000 | -42.0% | 193,113 | -44.2% | 0.00% | -50.0% |
| Q4 2020 | $8,712,000 | +69.1% | 346,240 | +40.1% | 0.00% | +100.0% |
| Q3 2020 | $5,151,000 | -9.2% | 247,195 | +3.4% | 0.00% | -50.0% |
| Q2 2020 | $5,676,000 | -38.7% | 238,965 | -53.6% | 0.00% | -33.3% |
| Q1 2020 | $9,262,000 | -44.1% | 514,850 | -26.3% | 0.00% | -25.0% |
| Q4 2019 | $16,581,000 | +88.4% | 699,013 | +118.3% | 0.00% | +33.3% |
| Q3 2019 | $8,799,000 | +56.8% | 320,204 | +88.9% | 0.00% | +50.0% |
| Q2 2019 | $5,610,000 | -44.7% | 169,531 | -41.5% | 0.00% | -33.3% |
| Q1 2019 | $10,150,000 | +36.1% | 289,652 | +29.0% | 0.00% | +50.0% |
| Q4 2018 | $7,459,000 | -53.2% | 224,527 | -29.1% | 0.00% | -50.0% |
| Q3 2018 | $15,948,000 | -40.3% | 316,748 | -29.1% | 0.00% | -42.9% |
| Q2 2018 | $26,735,000 | +25.1% | 446,702 | -4.3% | 0.01% | +40.0% |
| Q1 2018 | $21,370,000 | +100.0% | 466,597 | +74.0% | 0.01% | +66.7% |
| Q4 2017 | $10,686,000 | -11.3% | 268,147 | -11.0% | 0.00% | 0.0% |
| Q3 2017 | $12,054,000 | +36.5% | 301,323 | +47.1% | 0.00% | +50.0% |
| Q2 2017 | $8,829,000 | +58.1% | 204,839 | +14.8% | 0.00% | 0.0% |
| Q1 2017 | $5,586,000 | +1.2% | 178,482 | -18.4% | 0.00% | 0.0% |
| Q4 2016 | $5,521,000 | +7.1% | 218,662 | +5.0% | 0.00% | 0.0% |
| Q3 2016 | $5,153,000 | +559.0% | 208,336 | +442.3% | 0.00% | – |
| Q2 2016 | $782,000 | -4.4% | 38,414 | -28.4% | 0.00% | – |
| Q1 2016 | $818,000 | +80.2% | 53,616 | +58.7% | 0.00% | – |
| Q4 2015 | $454,000 | -74.5% | 33,776 | -67.8% | 0.00% | -100.0% |
| Q2 2015 | $1,779,000 | +763.6% | 104,799 | +514.8% | 0.00% | – |
| Q1 2015 | $206,000 | -31.1% | 17,047 | -52.6% | 0.00% | – |
| Q4 2014 | $299,000 | +119.9% | 35,992 | +130.0% | 0.00% | – |
| Q3 2014 | $136,000 | -4.2% | 15,651 | +20.5% | 0.00% | – |
| Q2 2014 | $142,000 | -45.8% | 12,984 | -55.7% | 0.00% | – |
| Q1 2014 | $262,000 | -67.7% | 29,280 | -72.8% | 0.00% | – |
| Q4 2013 | $812,000 | +515.2% | 107,741 | +485.7% | 0.00% | – |
| Q4 2012 | $132,000 | -38.3% | 18,394 | -0.8% | 0.00% | – |
| Q3 2012 | $214,000 | +29.7% | 18,542 | +5.5% | 0.00% | – |
| Q2 2012 | $165,000 | – | 17,581 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |